Crystallized oxalate decarboxylase and methods of use
Pharmaceutical compositions comprising spray-dried oxalate decarboxylase crystals are disclosed. Methods to treat a disorder associated with elevated oxalate concentration using compositions comprising spray-dried oxalate decarboxylase crystals are also disclosed.
1. A pharmaceutical composition comprising a capsule containing crystals of spray-dried oxalate decarboxylase comprising the amino acid sequence of SEQ ID NO:1, wherein the crystals have a Hausner ratio of about 1.00 to about 1.59.
2. The pharmaceutical composition of claim 1 , further comprising an excipient.
3. The pharmaceutical composition of claim 2 , wherein the excipient is a sugar.
4. The pharmaceutical composition of claim 3 , wherein the sugar is a disaccharide or a monosaccharide.
5. The pharmaceutical composition of claim 4 , wherein the sugar is selected from trehalose, sucrose, and glucose.
6. The pharmaceutical composition of claim 5 , wherein the sugar is trehalose.
7. The pharmaceutical composition of claim 1 , wherein the crystals have a Hausner ratio of about 1.00 to about 1.34.
8. The pharmaceutical composition of claim 7 , wherein the crystals have a Hausner ratio of about 1.00 to about 1.25.
9. The pharmaceutical composition of claim 8 , wherein the crystals have a Hausner ratio of about 1.00 to about 1.18.
10. The pharmaceutical composition of claim 9 , wherein the crystals have a Hausner ratio of about 1.12 to about 1.18.
11. The pharmaceutical composition of claim 8 , wherein the crystals have a Hausner ratio of about 1.19 to about 1.25.
12. The pharmaceutical composition of claim 7 , wherein the crystals have a Hausner ratio of about 1.26 to about 1.34.
13. The pharmaceutical composition of claim 1 , wherein the crystals have a Hausner ratio of about 1.34.
14. The pharmaceutical composition of claim 1 , wherein the crystals have a Hausner ratio less than 1.34.
15. The pharmaceutical composition of claim 1 , wherein the capsule comprises at least 3,000 U of oxalate decarboxylase crystals.
16. The pharmaceutical composition of claim 1 , wherein the capsule comprises at least 5,000 U of oxalate decarboxylase crystals.
17. The pharmaceutical composition of claim 1 , wherein the capsule comprises at least 6,000 U of oxalate decarboxylase crystals.
18. The pharmaceutical composition of claim 1 , wherein the capsule comprises between 6,000 U and 21,000 U of oxalate decarboxylase crystals.
19. The pharmaceutical composition of claim 15 , wherein the thiol moiety at Cys383 of the oxalate decarboxylase is protected by a reaction with a thiol protecting group.